SUMMARY In recent years sulphasalazine has gained acceptance as an effective agent for the treatment of rheumatoid arthritis. Ankylosing spondylitis is a disease where remission inducing drugs so far have been lacking. In this double blind trial sulphasalazine was compared with placebo in 37 patients with ankylosing spondylitis. Evaluation after three months' treatment showed reduction of inflammatory activity and improvement of clinical variables. The side effects were mild. The results suggest that sulphasalazine is a potentially effective and safe drug in the treatment of ankylosing spondylitis.
The mechanism by which SASP reduces the inflammatory activity in rheumatic diseases remains unknown. A documented anti-inflammatory effect of SASP in AS, however, might support the original theory of an intestinal mode of action of the drug, considering the importance of intestinal bacterial infections in other HLA-B27 associated arthritic lesions.4
In the present controlled, double blind study we confirm our preliminary results with SASP in AS and suggest this agent as a therapeutic alternative in this disease.
Patients and methods
The patients were recruited from consecutive outAccepted for publication 10 Of the clinical variables studied, stiffness (VAS), chest expansion, and degree of sleep disturbance showed significant improvement in the group with active treatment (Fig. 1) . These patients also improved in all other variables, but the changes did not reach statistical significance. Minor improvement or worsening of the disease was observed in the placebo group (Fig. 1) , with no significant improvement in any variable. The disease activity reflected by peripheral joint involvement was low in these patients. Only one out of 13 in the placebo group and one out of 14 in the SASP group suffered from peripheral synovitis. At the end of the study we found in the SASP treated group a decrease of ESR from 24.3±17.4 (SD) to 23-1±17-6 (NS), Orosomucoid g/l weeks haptoglobin from 2-94±0-96 to 2-14±0*93 (p>0.001), and orosomucoid from 1-42±049 to 1-26±0-48 (p-0-12). The individual changes of the acute phase plasma proteins are illustrated in Fig. 2 . In the placebo group no changes of these variables were observed (Table 2 ). There was no significant difference between the effects on the clinical variables in the SASP and placebo groups except for diminished sleep disturbance in the SASP group (p<002, Fisher's exact t test). The inflammatory activity defined by haptoglobin and orosomucoid was significantly improved (p<0-001 and <0-05 respectively) in the SASP group compared with the placebo group ( Table 2) . Analysis of individual values in the SASP group showed the greatest improvement in the patients with an ESR > 20 mm/h or haptoglobin > 3-8 g/l. 
Discussion
This study has shown the beneficial effects of SASP treatment in AS. It is the first study, to our knowledge, where a non-steroidal drug has improved both clinical and laboratory variables in AS, a disease where the use of remission inducing drugs so far has been lacking. The onset of clinical effects seems fairly similar to that reported in rheumatoid arthritis. 6 The improvement is usually obvious after eight weeks, so in most cases a 12 week test period should be sufficient. The side effects, as in RA, are mostly of the gastrointestinal type and mild. In our study we saw only one case of moderately severe allergic reaction. The side effects appear to be dose dependent, and we therefore recommend individualised dosage in future studies. No change in ESR was observed. The effect on the acute phase reaction defined by more sensitive variables (haptoglobin and orosomucoid) seems clear, though somewhat weaker than in rheumatoid arthritis. We do not interpret this as an effect of the prostaglandin inhibiting effects which have been ascribed to SASP, but as a possibly weak immunomodulatory mechanism of the drug.7 The effects on stiffness, pain, and sleep disturbance may be attributed to an effect similar to that of NSAIDs.8 9 We find the results in our study promising and take them as an indication of a possible alternative treatment in AS. Our experiences from open studies that SASP has the best effect in patients with inflammatory active disease is partly supported by this study.
The pathophysiological mechanisms in AS are still inadequately known. In reactive arthritis an associated infection in the gut, the urinary tract, or elsewhere is often present, but this is seldom evident in AS. There are theories that intestinal bacterial pathogens may influence the clinical course of AS."' In a genetically predisposed individual this may be due to either a direct effect of the viable bacteria or to an inadequate immune response to bacterial antigenic components, circulating immune complexes, or toxins." In this context a possible mode of action of SASP could be a local effect on the intestinal bacterial flora or a modulation of the intestinal immune system. 12 13 spondylitis. 
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